Glycologix, LLC

Beverly, MA · Founded 2021 · Biotech · Private

Biopolymers for soft tissue repair and bladder pain syndrome treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · glycologix.com

Sector: Biotech
Headquarters: Beverly, MA
Founded: 2021
Latest Form D: $800K, Dec 2025
Total capital: $8.8M

Federal grants: $3.6M; 3 awards · 2018–2021; Rank in peer group#273 of 514
Private capital raised: $5.2M; 4 Form D · last Dec 2025; 10 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 3; 3 pending · first 2021; Rank in peer group#109 of 514

Capital timeline

Latest events

Dec 2025Private capital raisedForm D · SEC · 4th filing$800K
Apr 2024Private capital raisedForm D · SEC · 3rd filing$1.5M
May 2023Private capital raisedForm D · SEC · 2nd filing$1.1M
Jan 2022Private capital raisedForm D · SEC · 1st filing$1.8M
Jul 2021Federal grantHealth and Human S · Phase II · SuperGAGs for Intravesicular Treatment of Interstitial Cystitis$1.3M
Jul 2020Federal grantHealth and Human S · Phase II · SuperGAGs for Intravesicular Treatment of Interstitial Cystitis$2M
Jun 2018Federal grantHealth and Human S · Phase I · SuperGAGs for Intravesicular Treatment of Interstitial Cystitis$288K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

43months

from Glycologix, LLC’s first federal award to its first private round.

First federal award · Jun 2018: Health and Human S · $288K
First Form D · Jan 2022: $1.8M · 1st Form D
Awards before first raise: 3 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#109 · top 21%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Daniel DeardorfExecutive Officer, DirectorNamed in SEC Form D filings
Douglas SmithExecutive OfficerNamed in SEC Form D filings
George AdaniyaDirectorNamed in SEC Form D filings
Martha FarmerDirectorNamed in SEC Form D filings
Michael ChesterDirectorNamed in SEC Form D filings
Michael MarshDirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 6

May 7, 2024GrantedSulfated Glycosaminoglycan Biomaterials As Proteoglycan MimicsUSPTOUS 11,975,019
Feb 27, 2024GrantedSulfated Glycosaminoglycan Biomaterials as Proteoglycan MimicsUSPTOUS 11,911,411
Aug 17, 2021GrantedSulfated Glycosaminoglycan Biomaterials as Proteoglycan MimicsUSPTOUS 11,090,327

Show all 6 patent records

Sulfated Glycosaminoglycan Biomaterials As Proteoglycan MimicsMay 7, 2024 · US 11,975,019Granted
Sulfated Glycosaminoglycan Biomaterials as Proteoglycan MimicsFeb 27, 2024 · US 11,911,411Granted
Sulfated Glycosaminoglycan Biomaterials as Proteoglycan MimicsAug 17, 2021 · US 11,090,327Granted
Sulfated Glycosaminoglycan Biomaterials as Proteoglycan MimicsApplication 62991804Pending
Sulfated Glycosaminoglycan Biomaterials As Proteoglycan MimicsApplication PCTUS2017051799Pending
Sulfated Glycosaminoglycan Biomaterials As Proteoglycan MimicsApplication 62395805Pending

CERTICHEM, INC.Similar federal contract value in Biotech · null in contracts
Viracta Subsidiary, Inc.Similar federal contract value in Biotech · null in contracts
ReproNovoSimilar federal contract value in Biotech · null in contracts
Tremeau Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Arbor Assets IncSimilar federal contract value in Biotech · null in contracts
Prothena Corp plcSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.